Clinical Trials

MODAG initiates first-in-patient phase 1b trial for Anle138b in Parkinson´s Disease

MODAG, a German biotechnology company focused on the development of disease-modifying small molecule therapeutics for neurodegenerative diseases, announced the clinical trial initiation of a first-in-patient Phase 1b study for anle138b in patients with mild to moderate Parkinson´s Disease (PD).

Lilly to begin pragmatic study of bamlanivimab for COVID-19 in New Mexico

Eli Lilly and Company announced plans to begin a new pragmatic study of bamlanivimab (LY-CoV555) in high-risk patients with COVID-19, in collaboration with major local institutions in the state of New Mexico.

Merck reports positive results for Keytruda, Lenvima combo in phase 3 KEYNOTE-775/Study 309 trial

Merck and Eisai announced that the pivotal Phase 3 KEYNOTE-775/Study 309 trial evaluating the investigational use of KEYTRUDA, Merck’s anti-PD-1 therapy, plus LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS) and its secondary efficacy endpoint of objective response rate (ORR) in patients with advanced endometrial cancer following at least one prior platinum-based regimen.

FSD Pharma doses first patient in phase 2 Covid-19 trial of FSD201

FSD Pharma has dosed the first patients in its phase 2a clinical trial designed to assess FSD201 (ultramicronised palmitoylethanolamide or ultramicronised PEA) for the treatment of hospitalised patients with Covid-19.

Novartis’ Kisqali demonstrates nearly five years median OS in metastatic breast cancer

Novartis announced updated median overall survival (OS) results for Kisqali (ribociclib) in combination with endocrine therapy, marking the longest survival data ever reported in premenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+HER2-) metastatic breast cancer.

AstraZeneca’s AZD1222 Covid-19 vaccine candidate delivers 70% efficacy

AstraZeneca and University of Oxford said that interim analysis of a phase 3 programme of the AZD1222 vaccine candidate (also called ChAdOx1 nCoV-19) is 70.4% effective in preventing symptomatic Covid-19 for more than 14 days after its second dose.

Inovio doses first patient in phase 2 segment of Covid-19 DNA vaccine candidate trial

Inovio Pharmaceuticals has dosed its first subject in phase 2 segment of its INNOVATE Phase 2/3 Clinical Trial for Covid-19 DNA vaccine candidate.

Pfizer, Sangamo announce updated results of phase 1/2 Alta study of giroctocogene fitelparvovec

Pfizer and Sangamo Therapeutics, a genomic medicines company, announced updated follow-up data from the Phase 1/2 Alta study of giroctocogene fitelparvovec (SB-525 or PF-07055480), an investigational gene therapy for patients with severe hemophilia A.

Sinovac receives up to $500m for Covid-19 vaccine development

Sinovac Life Sciences (Sinovac LS), a subsidiary of Sinovac, has received up to $500m in funding for the development of its Covid-19 vaccine candidate.